Status: Recruiting
5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors
This is a Phase I study to determine the optimal biological dose (OBD) of 5-Azacitidine in combination with PD-1/PD-L1 inhibitors in patients with tumors refractory to PD-1/PD-L1 inhibitors, for which such treatments have been approved.
Participants needed: 35
Trial details
Phase: Phase 1Age: 18-99Biological sex: AllType: InterventionalSponsor: Mohammed MilhemUpdated: May 28, 2026Locations: 1
Eligibility criteria
Written and voluntary informed consent. [+15]
Patients with a prior or concurrent malignancy whose natural history or treatmen... [+9]